Correlation of Alzheimer’s Disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers
PET neuroimaging of amyloid-beta (Aβ) provides an in vivo biomarker for pathologic changes associated with Alzheimer’s disease (AD). Aβ targeted agents have been approved by the FDA with additional agents, most notably targeting tau, currently under clinical investigation with one approved by the F...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Society for Nuclear Medicine
2020
|